Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., often referred to by its NASDAQ ticker ADIL, is a clinical-stage biopharmaceutical company primarily focused on developing treatments for addiction, with its lead investigational drug AD04 targeting Alcohol Use Disorder. In 2026, the company significantly expanded its pipeline by acquiring Azora Therapeutics, adding a new drug candidate for ulcerative colitis, and secured up to $64 million in financing to support its expanded development efforts. Despite reporting a narrower-than-expected loss in Q1 2026, the company remains pre-revenue, with its future tied to successful clinical trials and regulatory approvals.